Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Blood (2025) 146 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2025-1851

Published: 2025

Journal Articles

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer, Alex Herrera, Geoffrey Shouse, Daniel Ermann, Reem Karmali, Adam Kittai, Manali Kamdar, Diane Smith, James Godfrey, Brian Sworder, Swetha Thiruvengadam, John Baird, Avyakta Kallam, Elizabeth Budde, Alexey Danilov

Blood (2025) 146 (Supplement 1): 883.

https://doi.org/10.1182/blood-2025-883

Published: 2025

Journal Articles

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

Carla Casulo, Hongli Li, Alex Herrera, Sharon Castellino, Sarah Rutherford, Kelly Davison, Angela Punnett, Brad Kahl, John Leonard, Sonali Smith, Joo Song, Kara Kelly, Jonathan Friedberg, Michael Leblanc, Susan Parsons, Angie Mae Rodday, Andrew Evens

Blood (2025) 146 (Supplement 1): 154.

https://doi.org/10.1182/blood-2025-154

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani, Peter Riedell, Ajay Gopal, Leona Holmberg, Qian Wu, Sonali Smith, Mazyar Shadman

Blood (2025) 146 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2025-5483

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Aung Tun, Matthew Frank, Madiha Iqbal, Alex Herrera, Mehdi Hamadani, Waleska Pérez, Soyoung Kim, Babatunde Adedokun, Constance Lau, Kenny Hu, Timothy Best, Olga Nikolajeva, Grace Lee, Marcelo Pasquini, Caron Jacobson

Blood (2025) 146 (Supplement 1): 5356.

https://doi.org/10.1182/blood-2025-5356

Published: 2025

Journal Articles

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Anne-Ségolène Cottereau, Alex Herrera, Hervé Tilly, Gilles Salles, Loïc Chartier, Matthew Sugidono, Skander Jemaa, Richard Carano, Connie Lee Batlevi, Greg Hapgood, Georg Lenz, Franck Morschhauser

Blood (2025) 146 (Supplement 1): 5329.

https://doi.org/10.1182/blood-2025-5329

Published: 2025

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Lindsey Murphy, Molly Thornock, Xinyi Du, Alysia Bosworth, Lanie Lindenfeld, Matthew Mei, Leslie Popplewell, Nicole Karras, Anna Pawlowska, Alex Herrera, F. Wong, Stephen Forman, Elizabeth Budde, Saro Armenian

Blood (2025) 146 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2025-1013

Published: 2025

Journal Articles

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Amanda Chron, Kelsey Baron, Ashlee Joseph, Ayushi Chauhan, Sonia Godbole, Andrew Jallouk, Amy Ayers, Ajay Major, Swetha Thiruvengadam, Narendranath Epperla, Shakthi Bhaskar, Alex Herrera, Yazeed Sawalha, Sairah Ahmed, Gilles Salles, Lorenzo Falchi, Allison Bock

Blood (2025) 146 (Supplement 1): 958.

https://doi.org/10.1182/blood-2025-958

Published: 2025

Journal Articles

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

James Godfrey, Sravya Tumuluru, Alan Cooper, Gilles Salles, Marek Trneny, Georg Lenz, Franck Morschhauser, Fabrice Jardin, Will Harris, Sandhya Balasubramanian, Matthew Sugidono, Connie Lee Batlevi, Yanwen Jiang, Justin Kline, Alex Herrera

Blood (2025) 146 (Supplement 1): 49.

https://doi.org/10.1182/blood-2025-49

Published: 2025

Journal Articles

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

Blood (2025) 146 (Supplement 1): 471.

https://doi.org/10.1182/blood-2025-471

Published: 2025

Journal Articles

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL)

Kelly Davison, Joseph Unger, Hongli Li, Sharon Castellino, Hildy Dillon, Tricia Hernandez, Sarah Rutherford, Angela Punnett, Michael LeBlanc, Joo Song, Sonali Smith, Andrew Evens, Kara Kelly, Jonathan Friedberg, Alex Herrera, Susan Parsons

Blood (2025) 146 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2025-2738

Published: 2025

Journal Articles

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Blood (2025) 146 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2025-1841

Published: 2025

Journal Articles

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Blood (2025) 146 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2025-1837

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Karan Chohan, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

Blood (2025) 146 (Supplement 1): 5520.

https://doi.org/10.1182/blood-2025-5520

Published: 2025

Journal Articles

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Blood (2025) 146 (Supplement 1): 4515.

https://doi.org/10.1182/blood-2025-4515

Published: 2025

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Clinical prognostication in the SWOG 1826 randomized clinical trial of nivolumab-AVD versus brentuximab-AVD: Performance of the advanced-stage Hodgkin lymphoma international prognostic index (A-HIPI)

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Assessment of the prognostic value of FDG PET-derived markers and responses in POLARIX

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Transcriptional profiling refines DLBCL classification and identifies subtypes with distinct therapeutic vulnerabilities

Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL)

A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only